Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis

European Respiratory Journal

Volumn 45, Issue 5, 2015, Pages 1382-1392

  Ogura, Takashi ^a   Taniguchi, Hiroyuki ^b   Azuma, Arata ^c   Inoue, Yoshikazu ^d   Kondoh, Yasuhiro ^b   Hasegawa, Yoshinori ^e   Bando, Masashi ^f   Abe, Shinji ^c   Mochizuki, Yoshiro ^g   Chida, Kingo ^h   Klüglich, Matthias ⁱ   Fujimoto, Tsuyoshi ^j   Okazaki, Kotaro ^j   Tadayasu, Yusuke ^j   Sakamoto, Wataru ^j   Sugiyama, Yukihiko ^f  

^a Kanagawa Prefectural Cardiovascular and Respiratory Center Hospital   (Japan)

^b TOSEI GENERAL HOSPITAL   (Japan)

^c NIPPON MEDICAL SCHOOL   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

^e NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f JICHI MEDICAL UNIVERSITY   (Japan)

^g NATIONAL HOSPITAL ORGANIZATION HIMEJI MEDICAL CENTER   (Japan)

^h HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^j NIPPON BOEHRINGER INGELHEIM CO LTD   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CORTICOSTEROID; NINTEDANIB; PIRFENIDONE; PLACEBO; ENZYME INHIBITOR; INDOLE DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; PYRIDONE DERIVATIVE;

ABDOMINAL DISCOMFORT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FIBROSING ALVEOLITIS; GASTROINTESTINAL DISEASE; HUMAN; JAPANESE (PEOPLE); LIVER CANCER; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA; PHASE 2 CLINICAL TRIAL; PHOTOSENSITIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RHINOPHARYNGITIS; SIDE EFFECT; STEADY STATE; STOMATITIS; TREATMENT WITHDRAWAL; VOMITING; CLINICAL TRIAL; DOSE RESPONSE; IDIOPATHIC PULMONARY FIBROSIS; JAPAN; MIDDLE AGED; MULTICENTER STUDY; PATIENT SAFETY; TREATMENT OUTCOME; VITAL CAPACITY;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INDOLES; JAPAN; MALE; MIDDLE AGED; PATIENT SAFETY; PYRIDONES; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 84928998844     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00198013     Document Type: Article

References (19)

1. American Thoracic Society. Idiopathic pulmonary fibrosis: Diagnosis and treatment. International consensus statement. American Thoracic Society (ATS) and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000; 161: 646-664.
2. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis - evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788-824.
3. Fernandez IE, Eickelberg O. New cellular and molecular mechanisms of lung injury and fibrosis in idiopathic pulmonary fibrosis. Lancet 2012; 380: 680-688.
4. Wollin L, Maillet I, Quesniaux V, et al. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis. J Pharmacol Exp Ther 2014; 349: 209-220.
5. Hilberg F, Roth GJ, Krssak M, et al. BIBF 1120: Triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008; 68: 4774-4782.
6. Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011; 365: 1079-1087.
7. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2071-2082.
8. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): Two randomised trials. Lancet 2011; 377: 1760-1769.
9. King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2083-2092.
10. Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010; 35: 821-829.
11. Valeyre D, Albera C, Bradford WZ, et al. Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis. Respirology 2014; 19: 740-747.
12. European Medicines Agency. CHMP assessment report: Esbriet. www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public-assessment-report/human/002154/WC500103073.pdfDate last updated: December 16, 2010. Date last accessed: September 4, 2013.
13. Stopfer P, Rathgen K, Bischoff D, et al. Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers. Xenobiotica 2011; 41: 297-311.
14. Japanese Respiratory Society. Idiopathic interstitial pneumonias: Diagnosis and treatment. Nankodo 2004; 36-40.
15. Pulmonary Physiology Specialist Committee of the Japanese Respiratory Society. Predicted values of spirometry and arterial blood gas analysis in Japanese. J Jpn Respir Soc 2001; 39: 1-17.
16. Raghu G, Johnson WC, Lockhart D, et al. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study. Am J Respir Crit Care Med 1999; 159: 1061-1069.
17. Mross K, Stefanic M, Gmehling D, et al. Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors. Clin Cancer Res 2010; 16: 311-319.
18. Reck M, Kaiser R, Eschbach C, et al. A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer. Ann Oncol 2011; 22: 1374-1381.
19. Okamoto I, Kaneda H, Satoh T, et al. Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors. Mol Cancer Ther 2010; 9: 2825-2833.